Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celltrion And Teva Catch Up On Canadian Trastuzumab

Sep 13 2019

• By David Wallace

Canada_Thumbs_Up — Health Canada has approved Celltrion and Teva’s trastuzumab biosimilar • Source: Shutterstock

Related Content

Teva Gets Canadian Rituximab Nod, But Barriers May Remain

Apr 15 2019

Celltrion’s Herzuma receives Europe nod

Feb 23 2018

Further Victory For Celltrion and Teva, As Their Trastuzumab Biosimilar, Herzuma, Receives FDA Approval

Dec 17 2018

Mylan Prepares To Launch Canada's First Trastuzumab Within Weeks

May 28 2019

Additional Topics

Canada Biosimilars Regulation BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.